Rapid, Focused Enrollment in Early Phase Obesity Clinical Trials

In a Phase 1 Obesity study of an injectable incretin biologic, three ERG sites enrolled 99 participants in under four weeks, exceeding the contracted goal and compensating for under performance at non-network site.

Key Elements

  • Exceeded contract goals
  • Coordinated multi-site strategy
  • ERG contributed 75% of sites and 82.5% of enrolled subjects

99

Participants Enrolled

4

Week Enrollment Period

82.5%

of Participants were enrolled by ERG

Challenges

The study targeted a healthy but obese population and included complex testing requirements such as advanced imaging for body composition and adipose compartmentalization, physical function tests, and patient reported outcomes.

Continually Expanding Obesity Database

ERG exclusive database of over 200,000 overweight and obese participants across the ERG network. The result is a diverse, engaged participant population that is ready for rapid enrollment.

Complex Testing Onsite

Complex testing on site included physical functions test: 6-minute walking test, repeat chair stand, 12-step stair climb test.

Wholly Owned Clinical Sites

ERG readily support sponsors in the design and execution of obesity clinical trials with a portfolio of 20 wholly owned sites with scalable infrastructure spanning major metropolitan area and regional hubs. 

Get in Touch

ERG’s mission is to provide the highest quality clinical trial execution across all clinical research phases to help sponsors.